Health Education Articles | PlexusDx – Tagged "triple-agonist"

GLP-3 retatrutide pipeline triple-agonist explained — how PlexusDx compounded semaglutide and tirzepatide compare in 2026

GLP-3 Retatrutide Explained: Pipeline Triple-Agonist in 2026

GLP-3 retatrutide explained: triple-agonist mechanism, Phase 3 TRIUMPH data, dysesthesia signal, FDA timeline, and how PlexusDx’s currently-available compounded semaglutide and tirzepatide protocols compare to the pipeline asset.

Disclaimer: The products promoted on this page are intended strictly for laboratory and scientific research use only. They are not approved by the FDA for human consumption, diagnosis, or clinical treatment. Portions of this page contain affiliate links, meaning we earn a commission if you make a purchase through our partner links at no extra cost to you.

Premium Research-Grade Peptides
3rd Party Tested | +99% Pure | Made in USA

Shop Research Peptides →

Retatrutide vs orforglipron vs PlexusDx — pipeline GLP-1 comparison and currently-available compounded options for 2026

Retatrutide vs Orforglipron vs PlexusDx (2026): Pipeline GLP-1s, Real-World Options

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols (

Keep in Touch

Subscribe to our newsletter and stay up-to-date on new reports, tests, and health tips designed to help you live your healthiest life.

Important information about your prescription program.

PlexusDx is not a medical practice or pharmacy. Using this website does not create a doctor-patient relationship between you and PlexusDx.

Clinical services are provided by an independent network of U.S.-licensed clinicians through a state-licensed telehealth platform. Compounded medications are dispensed by state-licensed compounding pharmacies operating in FDA-registered facilities. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.

If you would prefer a branded, FDA-approved prescription medication, your provider may write a prescription that you can fill at the pharmacy of your choice. PlexusDx does not sell or ship branded prescription medications.

Medication and clinical service fees are billed and collected by the practice-management platform that supports the prescribing clinicians. PlexusDx is paid separately for the data, referral, and customer-experience services that PlexusDx provides. PlexusDx is not the merchant of record for any prescription medication.

The GLP-1 & Peptide Pathways Genetic Test and any other genetic test or report sold by PlexusDx is intended to provide personalized educational information about your biology. It does not recommend, prescribe, or determine which medications a customer should use. Treatment decisions are made by your independent prescribing clinician based on your full medical history.

Product images on this site are illustrative and may not represent actual product packaging.

Individual results vary. Statements regarding outcomes are not guarantees and have not been evaluated by the FDA.

All content on this site is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always seek the advice of a qualified clinician with any questions you may have about a medical condition or treatment.

Ozempic®, Wegovy®, Rybelsus®, Zepbound®, and Mounjaro® are registered trademarks of their respective owners and are not affiliated with PlexusDx.